Side-by-side · Research reference
HumaninvsSNAP-8
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED14/52 cited
BHuman-MechanisticHUMAN-REVIEWED8/46 cited
Humanin
Mitochondrial-Derived Peptide · Cytoprotective
SQ · Experimental
SNAP-8
Synthetic Octapeptide · Cosmetic Topical
TopicalRoute
8-AAPeptide length
SNAREPrimary target
Topical · Facial application · Twice daily
01Mechanism of Action
Parameter
Humanin
SNAP-8
Primary target
Intracellular: Bax, Bim, tBid (pro-apoptotic Bcl-2 family). Extracellular: FPRL1/2 G-protein-coupled receptorsZhu 2022Lue 2021
SNARE complex (SNAP-25 competitive binding site)
Pathway
Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival
Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation
Downstream effect
Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022Lue 2021Velentza 2024
Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction
Feedback intact?
Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis
N/A — topical cosmetic, no systemic endocrine axis
Origin
Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022Shahzaib 2026
Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)
Antibody development
Not reported in animal models
—
02Dosage Protocols
Parameter
Humanin
SNAP-8
Standard experimental dose (HNG)
4 mg/kg IP (rat)
Most common dose in rodent models.
—
Ex vivo bone culture
1 µg/mL
Protective against venetoclax-induced bone growth retardation.
—
Frequency
Daily (IP)
—
Duration
8–12 weeks in animal studies
—
Evidence basis
Animal models (rat, mouse)Huang 2025El 2022Velentza 2024
RCT, in vitro skin penetration studies
Human data
None — no clinical trials reported
—
Analog (HNG)
Gly[14]-humanin — more potent variant
Substitution at position 14 enhances cytoprotective activity.
—
Typical concentration
—
2–10% in cosmetic formulationsLupin 2024Raikou 2017
Commercial products typically use 5–10%.
Treatment duration
—
20–60 days for visible effectRaikou 2017
Skin microtopography improvements measured at 20-day intervals.
Formulation type
—
Oil-in-water emulsion, serum, cream
Application site
—
Facial skin — glabellar lines, crow's feet, forehead
03Metabolic / Fat Loss Evidence
Parameter
Humanin
SNAP-8
Direct fat loss evidence
None
—
Mechanism overlap
Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect
—
04Side Effects & Safety
Parameter
Humanin
SNAP-8
Animal model safety
Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks
—
Human safety data
None — no clinical trials
—
Theoretical fibrillation risk
Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.
—
Injection site reaction
Not reported in animal studies (IP route)
—
Reproductive safety
Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025
—
Cytotoxicity
—
Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)
Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.
Skin irritation
—
Minimal; well-tolerated in clinical use
Peptide oxidation
—
Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021
Formulation stability issue, not a direct adverse effect.
Hypersensitivity
—
Rare; no widespread allergic reactions reported
Absolute Contraindications
Humanin
- ·Unknown — no human data
SNAP-8
- ·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients
Relative Contraindications
Humanin
- ·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)
SNAP-8
- ·Active skin infections or open wounds at application site
- ·Neuromuscular disorders (theoretical concern, no documented cases)
05Administration Protocol
Parameter
Humanin
SNAP-8
1. Route (experimental)
Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.
Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.
2. Reconstitution
Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.
Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.
3. Timing
Daily administration in animal studies. Optimal timing not characterized.
Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.
4. Storage
Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.
Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.
5. Human use
No FDA approval, no IND, no clinical trials. Experimental research tool only.
Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.
6. Duration
—
Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.
06Stack Synergy
Humanin
+ MOTS-c
Multi-pathwayBoth are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.
- Humanin
- 4 mg/kg IP · daily (animal model)
- MOTS-c
- 5 mg/kg IP · daily (animal model)
- Frequency
- Once daily
- Primary benefit
- Mitochondrial health, metabolic efficiency, anti-apoptotic signaling
SNAP-8
— no documented stacks